Sanofi offloads 17 brands to Neuraxpharm

After similar deals in April and June, French pharma juggernaut Sanofi is selling off another clutch of established meds in a move consistent with CEO Paul Hudson’s “play to win” strategy.

Sanofi has entered a deal to hand over 17 branded products to central nervous system (CNS) specialist Neuraxpharm for an undisclosed sum. The drugs comprise two product portfolios for CNS disorders, pain and vascular diseases, Neuraxpharm said in a release.